Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer (NCT02657889)
The University of Virginia Cancer Center frequently opens new clinical trials, offering your patients the latest investigational treatments. For a complete list of active trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website.
If you have patients who may be eligible to participate in a clinical trial, please email firstname.lastname@example.org.
Metastatic Triple-Negative Breast Cancer (IRB-HSR #19307)
Prostate Cancer (IRB-HSR #19583)
A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer (NCT02799602)
Metastatic Urothelial Carcinoma (IRB-HSR #19436)
Ovarian Cancer (IRB-HSR #19128)
A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer (NCT02718417)
Advanced Malignancies (IRB-HSR #18488)
Metastatic Solid Tumors (IRB-HSR #19390)
First In-Human, Dose-Escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate (Humax®-TF-ADC) In Patients with Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor (NCT02001623)